Increased susceptibility of fibroblasts from horses with severe combined immunodeficiency to growth inhibition by 2′-deoxyadenosine.

This research study explores the effect of four purines on the growth rate of various fibroblasts. It finds that deoxyadenosine inhibits growth more in fibroblasts from horses with severe combined immunodeficiency (SCID), suggesting a potential defect in transport or utilization of deoxyATP in such horses.

Examination of Purines on Fibroblast Growth

• The study investigates the influence of four different purines (adenosine, deoxyadenosine, guanosine, and deoxyguanosine) on the growth rate of fibroblasts from regular horses, horses heterozygous for the SCID trait, and horses with SCID.
• It was found that all the investigated purines had the ability to slow down growth, depending on the dosage. However, only adenosine and deoxyadenosine were found to inhibit growth at concentrations of less than 100 microM.

Sensitivity to Adenosine and Deoxyadenosine

• The data showed no statistical difference when comparing regular and SCID fibroblast sensitivity to adenosine.
• Contrarily, fibroblasts from SCID horses were found to be more susceptible to the growth inhibitory effects of deoxyadenosine in comparison to fibroblasts from normal horses.

Analysis of DeoxyATP Concentrations

• A side-by-side comparison was conducted by incubating both SCID and normal fibroblasts with radiolabeled deoxyadenosine for 24 hours.
• The result demonstrated a twofold increase in radiolabeled deoxyATP concentrations in SCID fibroblasts relative to normal fibroblasts, which were grown under the same conditions.

Investigation of Underlying Biological Mechanisms

• The researchers found no anomalies in adenosine deaminase and S-adenosylhomocysteine hydrolase activities, two enzymes involved in deoxyadenosine metabolism, in the SCID fibroblasts.
• Based on these results, the researchers propose that horses with SCID could have a functional defect either in the transportation or phosphorylation of deoxyadenosine, or in the utilization of deoxyATP.

Implications of Research

• The findings point to a potential vulnerability in SCID horses specific to deoxyadenosine, possibly indicating a metabolic abnormality. Such information could be valuable in advancing the understanding of SCID in horses, paving the way for better targeted treatments.